Breaking News Instant updates and real-time market news.

GILD

Gilead

$79.12

1.26 (1.62%)

, MRK

Merck

$62.41

0.5 (0.81%)

07:47
10/03/16
10/03
07:47
10/03/16
07:47

AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink

Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.

GILD

Gilead

$79.12

1.26 (1.62%)

MRK

Merck

$62.41

0.5 (0.81%)

ABBV

AbbVie

$63.07

0.25 (0.40%)

  • 04

    Oct

  • 07

    Oct

  • 25

    Oct

  • 06

    Nov

  • 11

    Nov

GILD Gilead
$79.12

1.26 (1.62%)

09/27/16
LEER
09/27/16
DOWNGRADE
Target $94
LEER
Market Perform
Gilead downgraded to Market Perform from Outperform at Leerink
Leerink analyst Geoffrey Porges downgraded Gilead Sciences to Market Perform from Outperform and lowered his price target for the shares to $94 from $112. The biotech closed yesterday down 75c to $80.62. The analyst says he's now "outright bearish" on the company's Hepatitis C virus business. Gilead's HCV revenues will "decline faster, and farther," than the current consensus estimates forecast, Porges tells investors in a research note.
09/22/16
JANY
09/22/16
NO CHANGE
Target $64
JANY
Buy
Galapagos drug more important to Gilead after trial halt, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Gilead Sciences' (GILD) termination of its combined Phase 2/3 study of GS-5745 in ulcerative colitis implies that Galapagos (GLPG) filgotinib is now potentially more important to Gilead's growth prospects. The analyst, who thinks upcoming data could provide meaningful upside for Galapagos shares even after the stock's 25% move up over the past three weeks, keeps a Buy rating and $64 fair value estimate on the stock.
09/22/16
LEER
09/22/16
NO CHANGE
LEER
Outperform
Gilead trial suspension another blow to R&D strategy, says Leerink
Leerink analyst Geoffrey Porges believes Gilead's suspension of Phase 2/3 for GS-5745, its anti-matrix metalloproteinase 9 anti-body for the treatment of ulcerative colitis, is unlikely to significantly impact revenue forecasts for the company. However, he sees the announcement as another blow to the sentiment about the company's R&D prospects and investor sentiment. Further, Porges notes that GS-5745 was one of the five proof-of-concept molecules in Phase 2 development that offered opportunity for some offset to Gilead's "increasingly challenged" core businesses. He reiterates an Outperform rating on the shares.
09/27/16
09/27/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Gilead (GILD) downgraded to Market Perform from Outperform at Leerink with analyst Geoffrey Porges saying he's now "outright bearish" on the company's Hepatitis C virus business. 2. J.M. Smucker (SJM) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Moskow saying that while the company raised its cost savings target as expected, he underestimated the hit to sales from difficult comparisons. 3. Discovery (DISCA) and Scripps Networks (SNI) downgraded to Sell from Neutral at MoffettNathanson. 4. Carter's (CRI) downgraded to Market Perform from Outperform at Wells Fargo with analyst Ike Boruchow saying his quarter-to-date store checks indicate "choppy" retail traffic trends and "deeper" pricing/promotional pressure. 5. Dollar Tree (DLTR) downgraded to Underweight from Neutral at Atlantic Equities with analyst Sam Hudson saying the second half comp inflection expected by consensus is "too demanding" and he expects multiple contraction if Family Dollar does not turn around. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MRK Merck
$62.41

0.5 (0.81%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
08/15/16
BERN
08/15/16
NO CHANGE
BERN
Survey of MDs suggest Merck's Keytruda being underestimated, says Bernstein
After Bernstein surveyed a total of 79 U.S. and EU doctors, analyst Tim Anderson says the impact of recent trials of Merck's (MRK) Keytruda and Bristol-Myers' (BMY) Opdivo will be "greater than many (investors) expect." Anderson says that the survey indicates that the positive implications on Merck and the negative impact on Bristol-Myers will not just be "a near-term phenomenon." The analyst continues to expect the impact of the recent data to be greater than the consensus outlook. He keeps a $74 price target and Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
08/19/16
UBSW
08/19/16
NO CHANGE
Target $70
UBSW
Buy
Merck price target raised to $70 from $62 at UBS
UBS analyst Marc Goodman raised his price target on Merck (MRK) to $70 from $62 as he updated his model to account for a more favorable Keytruda opportunity following the failed CheckMate-026 trial at Bristol-Myers (BMY). The analyst also feels investors do not give enough credit to Merck's Januvia franchise or the potential for growth opportunity from the pipeline. Goodman reiterated his Buy rating on Merck shares.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
ABBV AbbVie
$63.07

0.25 (0.40%)

09/08/16
JPMS
09/08/16
DOWNGRADE
Target $73
JPMS
Neutral
AbbVie downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Chris Schott downgraded AbbVie (ABBV) to Neutral citing the stock's 10% rally year-to-date and limited near-term catalysts. AbbVie's profile is now better reflected at current valuation levels, Schott tells investors in a research note. He lowered his price target for the shares to $73 from $75. The analyst coupled the downgrade with an upgrade this morning of Eli Lilly (LLY) to Overweight.
09/02/16
09/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AbbVie (ABBV) initiated with an Outperform at Raymond James. 2. Spark Therapeutics (ONCE) initiated with a Buy at Stifel. 3. Cornerstone OnDemand (CSOD) initiated with an Overweight at Piper Jaffray. 4. UR-Energy (URG) initiated with an Outperform at FBR Capital. 5. Energy Transfer Equity (ETE) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/01/16
RAJA
09/01/16
INITIATION
Target $82
RAJA
Outperform
AbbVie initiated with an Outperform at Raymond James
Target $82.
07/14/16
JEFF
07/14/16
NO CHANGE
JEFF
AbbVie remains Jefferies' Top Pick in Global Pharma
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his firm's Top Pick in Global Pharmaceuticals, followed by Eli Lilly (LLY), Novartis (NVS), GlaxoSmithKline (GSK) and Zoetis (ZTS). The analyst this morning upgraded GSK to Buy from Hold. Holford also remains positive on Roche (RHHBY), Abbott (ABT) and Pfizer (PFE). The analyst's least preferred names are Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Merck (MRK). The Q2 earnings season offers "few clear beat and raise" stories and looks weakest for AstraZeneca (AZN) against preliminary consensus, Holford tells investors in a pre-earnings research note.

TODAY'S FREE FLY STORIES

OHI

Omega Healthcare

$34.61

-0.05 (-0.14%)

13:35
06/27/17
06/27
13:35
06/27/17
13:35
Options
Omega Healthcare put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:35
06/27/17
06/27
13:35
06/27/17
13:35
General news
Fed Chair Yellen hasn't said anything obvious on the policy front yet »

Fed Chair Yellen…

RATE

Bankrate

$12.33

-0.125 (-1.00%)

13:33
06/27/17
06/27
13:33
06/27/17
13:33
Periodicals
Bankrate jumps after rumor report published by Betaville »

Shares of Bankrate have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$157.50

-0.52 (-0.33%)

13:27
06/27/17
06/27
13:27
06/27/17
13:27
Technical Analysis
Technical View: Netflix trades near session lows »

The stock is down over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

VRX

Valeant

$17.11

0.03 (0.18%)

13:25
06/27/17
06/27
13:25
06/27/17
13:25
Recommendations
Valeant analyst commentary  »

Valeant debt-for-equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

AGNC

AGNC Investment

$22.28

0.07 (0.32%)

13:25
06/27/17
06/27
13:25
06/27/17
13:25
Options
AGNC Investment Corp. call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

13:20
06/27/17
06/27
13:20
06/27/17
13:20
General news
Treasury Action: yields extended their surge »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

13:17
06/27/17
06/27
13:17
06/27/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
06/27/17
06/27
13:16
06/27/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$24.27

0.25 (1.04%)

, XLK

Technology Select Sector SPDR

$55.52

-0.48 (-0.86%)

13:15
06/27/17
06/27
13:15
06/27/17
13:15
Technical Analysis
Technical View: S&P 500 mid-session chart update »

The S&P 500 (SPX) did…

XLF

Financial Select Sector

$24.27

0.25 (1.04%)

XLK

Technology Select Sector SPDR

$55.52

-0.48 (-0.86%)

SPY

SPDR S&P 500 ETF Trust

$242.76

-0.53 (-0.22%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.59

-1.48 (-0.95%)

13:08
06/27/17
06/27
13:08
06/27/17
13:08
Hot Stocks
Facebook reaches two billion users, Zuckerberg says »

Facebook CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

AVAV

AeroVironment

$30.97

0.2 (0.65%)

13:07
06/27/17
06/27
13:07
06/27/17
13:07
Conference/Events
AeroVironment management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 03

    Jul

  • 04

    Jul

  • 05

    Jul

CBI

CB&I

$19.00

4.6 (31.94%)

13:05
06/27/17
06/27
13:05
06/27/17
13:05
Options
CB&I call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$109.93

-0.12 (-0.11%)

13:05
06/27/17
06/27
13:05
06/27/17
13:05
Hot Stocks
Quest Diagnostics announces intent to acquire CCHC outreach lab business »

Quest Diagnostics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

FOX

21st Century Fox

$27.62

0.69 (2.56%)

, FOXA

21st Century Fox

$28.04

0.85 (3.13%)

12:57
06/27/17
06/27
12:57
06/27/17
12:57
Hot Stocks
FOX Sports partners with Facebook to stream Champions League soccer »

Twenty-First Century…

FOX

21st Century Fox

$27.62

0.69 (2.56%)

FOXA

21st Century Fox

$28.04

0.85 (3.13%)

FB

Facebook

$153.59

-1.48 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

DHXM

DHX Media

$4.15

-0.0367 (-0.88%)

12:56
06/27/17
06/27
12:56
06/27/17
12:56
Conference/Events
DHX Media management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

IVZ

Invesco

$35.01

-0.005 (-0.01%)

12:55
06/27/17
06/27
12:55
06/27/17
12:55
Conference/Events
Invesco management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

FDX

FedEx

$215.36

-0.0025 (-0.00%)

12:52
06/27/17
06/27
12:52
06/27/17
12:52
Periodicals
TNT Express says hit with 'interference' with some of its systems, ABC News says »

A spokesman for TNT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jul

FDX

FedEx

12:50
06/27/17
06/27
12:50
06/27/17
12:50
Periodicals
FedEx 'operating normally' after functionality issues, Reuters reports »

A spokeswoman for FedEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jul

THC

Tenet

$19.43

0.6587 (3.51%)

12:50
06/27/17
06/27
12:50
06/27/17
12:50
Options
3K Tenet Healthcare Jul 20 calls trade for 88c »

3K Tenet Healthcare Jul…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

AMZN

Amazon.com

$993.98

-9.76 (-0.97%)

, WFM

Whole Foods

$42.69

-0.255 (-0.59%)

12:48
06/27/17
06/27
12:48
06/27/17
12:48
Hot Stocks
Kroger CEO: Whole Foods 'great fit' for Amazon »

Speaking in a CNBC…

AMZN

Amazon.com

$993.98

-9.76 (-0.97%)

WFM

Whole Foods

$42.69

-0.255 (-0.59%)

KR

Kroger

$22.97

0.355 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

SMSMY

Sims Metal

$10.30

-0.03 (-0.29%)

12:47
06/27/17
06/27
12:47
06/27/17
12:47
Upgrade
Sims Metal rating change  »

Sims Metal upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
06/27/17
06/27
12:45
06/27/17
12:45
General news
Breaking General news story  »

Federal Reserve Chair…

12:45
06/27/17
06/27
12:45
06/27/17
12:45
Conference/Events
Federal Reserve Board Chair Yellen speaks on global economic issues »

Federal Reserve Board…

DD

DuPont

$80.85

-0.31 (-0.38%)

, DOW

Dow Chemical

$63.30

-0.27 (-0.42%)

12:43
06/27/17
06/27
12:43
06/27/17
12:43
Periodicals
Mexico's Cofece grants conditional approval of DuPont-Dow tie-up, Reuters says »

Mexico's Federal…

DD

DuPont

$80.85

-0.31 (-0.38%)

DOW

Dow Chemical

$63.30

-0.27 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.